These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30954777)

  • 21. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
    Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions.
    Mohareb RM; Abouzied AS; Abbas NS
    Anticancer Agents Med Chem; 2019; 19(12):1438-1453. PubMed ID: 31038076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of Tetrahydrobenzo[
    Mohareb RM; Wardakhan WW; Abbas NS
    Anticancer Agents Med Chem; 2019; 19(14):1737-1753. PubMed ID: 30947678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
    Wu B; Wang HL; Cee VJ; Lanman BA; Nixey T; Pettus L; Reed AB; Wurz RP; Guerrero N; Sastri C; Winston J; Lipford JR; Lee MR; Mohr C; Andrews KL; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):775-80. PubMed ID: 25616902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
    Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
    J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study.
    Farrag AM; Ibrahim MH; Mehany ABM; Ismail MMF
    Bioorg Chem; 2020 Dec; 105():104378. PubMed ID: 33099167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
    Abouzid KAM; Al-Ansary GH; El-Naggar AM
    Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
    Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of quinones as novel PIM1 kinase inhibitors.
    Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety.
    Moreau P; Anizon F; Giraud F; Esvan YJ
    Recent Pat Anticancer Drug Discov; 2016; 11(3):309-21. PubMed ID: 27194556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
    Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
    Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
    Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
    Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
    Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
    Panchal NK; Sabina EP
    Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
    Xia Z; Knaak C; Ma J; Beharry ZM; McInnes C; Wang W; Kraft AS; Smith CD
    J Med Chem; 2009 Jan; 52(1):74-86. PubMed ID: 19072652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
    Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.